Loading articles...
Patients on lorlatinib require vigilant monitoring for hyperglycemia and ketoacidosis, regardless of pre-existing diabetes risk factors. Proactive screening and early intervention are crucial to mitigate potential severe complications and ensure patient saf...
Patients on lorlatinib may develop diabetes with unusual characteristics, including the absence of typical autoantibodies. This presents a diagnostic challenge, requiring clinicians to consider drug-induced etiologies even when initial immunological markers...
Patients on lorlatinib should be monitored for hyperglycemia, regardless of autoantibody status. This case raises concerns about potential metabolic toxicities of ALK inhibitors beyond what is currently recognized.
The VICTORION-PLAQUE trial in primary prevention evaluates inclisiran, a small interfering RNA targeting PCSK9, for effects on atherosclerotic plaque using prespecified multimodality imaging endpoints. Randomized and double-blind, with dosing at day 1, day ...